WAVE Life Sciences Ltd.
WVE
$13.02
-$0.33-2.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.25M | 7.61M | 8.70M | 9.18M | 83.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.25M | 7.61M | 8.70M | 9.18M | 83.75M |
| Cost of Revenue | 52.81M | 45.87M | 43.47M | 40.62M | 44.65M |
| Gross Profit | -35.57M | -38.27M | -34.77M | -31.45M | 39.10M |
| SG&A Expenses | 20.90M | 18.09M | 17.99M | 18.36M | 16.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.71M | 63.96M | 61.46M | 58.98M | 60.78M |
| Operating Income | -56.47M | -56.35M | -52.76M | -49.80M | 22.97M |
| Income Before Tax | -53.18M | -53.85M | -50.47M | -46.88M | 29.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.18M | -53.85M | -50.47M | -46.88M | 29.25M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.18M | -53.85M | -50.47M | -46.88M | 29.25M |
| EBIT | -56.47M | -56.35M | -52.76M | -49.80M | 22.97M |
| EBITDA | -55.62M | -55.50M | -51.89M | -48.93M | 23.87M |
| EPS Basic | -0.30 | -0.32 | -0.31 | -0.29 | 0.18 |
| Normalized Basic EPS | -0.18 | -0.20 | -0.19 | -0.18 | 0.11 |
| EPS Diluted | -0.30 | -0.32 | -0.31 | -0.29 | 0.17 |
| Normalized Diluted EPS | -0.18 | -0.20 | -0.19 | -0.18 | 0.11 |
| Average Basic Shares Outstanding | 180.28M | 167.74M | 163.99M | 162.53M | 161.49M |
| Average Diluted Shares Outstanding | 180.28M | 167.74M | 163.99M | 162.53M | 172.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |